organization · Reporting owner
Samsara Opportunity Fund GP, LLC
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Kalaris Therapeutics, Inc.KLRS · Entity 6805 | 10% owner | May 20, 2026 | May 22, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Kalaris Therapeutics, Inc.
Report date May 20, 2026 · Filed May 22, 2026
Jointly reported with AKKARAJU SRINIVAS, Samsara BioCapital, L.P., Samsara BioCapital GP, LLC, Samsara Opportunity Fund, L.P.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Samsara Opportunity Fund, L.P. | 2,224,147 |
Reported balance
After 2026-05-20 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2026-05-20 · Purchase · Acquired 244,300 · Balance 2,224,147 F1: Represents the purchase of shares from Samsara BioCapital, L.P. ("Samsara LP") in a privately negotiated transaction. F2: Securities are directly held by Samsara Opportunity Fund, L.P. ("Samsara Opportunity Fund"). Samsara Opportunity Fund GP, LLC ("Samsara Opportunity GP") is the general partner of Samsara Opportunity Fund and may be deemed to beneficially own the securities held by Samsara Opportunity Fund. Dr. Srinivas Akkaraju, MD, Ph.D. has voting and investment power over the securities held by Samsara Opportunity Fund and, accordingly, may be deemed to beneficially own the securities held by Samsara Opportunity Fund. Each of the Reporting Persons disclaims beneficial ownership in these securities except to the extent of its or his pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy Samsara BioCapital, L.P. | 10,657,028 |
Reported balance
After 2026-05-20 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2026-05-20 · Other · Disposed 66,906 · Balance 10,657,028 F3: Represents a pro rata, in-kind distribution, without additional consideration, and not a purchase or sale of securities, by Samsara LP in respect of redeemed interests in Samsara LP. Of the shares distributed by Samsara LP, (i) 47,498 were distributed to redeeming limited partners, (ii) 14,937 shares were distributed to Samsara BioCapital GP, LLC ("Samsara LLC"), the general partner of Samsara LP, in respect of redeemed interests of non-managing members of Samsara LLC that were retained by Samsara LLC, and (iii) 4,471 shares were distributed to Samsara BioCapital Partners, L.P. ("Samsara BioCapital Partners"), in respect of the redeemed interest of a limited partner of Samsara LP that has been acquired by Samsara BioCapital Partners. F4: The shares held by Samsara LP reflects the disposition of 244,300 shares, to Samsara Opportunity Fund as described in footnote (1), in which each of Samsara LLC and Dr. Akkaraju had no pecuniary interest. F5: Securities are held by Samsara LP. Samsara LLC is the general partner of Samsara LP and may be deemed to beneficially own the shares held by Samsara LP. Dr. Akkaraju has voting and investment power over the shares held by Samsara LP and, accordingly, may be deemed to beneficially own the shares held by Samsara LP. Each of the Reporting Persons disclaims beneficial ownership in these shares except to the extent of its or his respective pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy Samsara BioCapital GP, LLC | 14,937 |
Reported balance
After 2026-05-20 transaction · row 3
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 3 · 2026-05-20 · Other · Acquired 14,937 · Balance 14,937 F6: Represents receipt of shares in the distribution in kind described in footnote (3). F7: Securities are held by Samsara LLC. Dr. Akkaraju has voting and investment power over the shares held by Samsara LLC and, accordingly, may be deemed to beneficially own the shares held by Samsara LLC. Each of the Reporting Persons disclaims beneficial ownership in these shares except to the extent of its or his respective pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy Samsara BioCapital Partners, L.P. | 19,408 |
Reported balance
After 2026-05-20 transaction · row 4
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 4 · 2026-05-20 · Other · Acquired 4,471 · Balance 19,408 F6: Represents receipt of shares in the distribution in kind described in footnote (3). F8: Securities are held by Samsara BioCapital Partners. Dr. Akkaraju has voting and investment power over the shares held by Samsara BioCapital Partners and, accordingly, may be deemed to beneficially own the shares held by Samsara BioCapital Partners. Each of the Reporting Persons disclaims beneficial ownership in these shares except to the extent of its or his respective pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the purchase of shares from Samsara BioCapital, L.P. ("Samsara LP") in a privately negotiated transaction.
F2: Securities are directly held by Samsara Opportunity Fund, L.P. ("Samsara Opportunity Fund"). Samsara Opportunity Fund GP, LLC ("Samsara Opportunity GP") is the general partner of Samsara Opportunity Fund and may be deemed to beneficially own the securities held by Samsara Opportunity Fund. Dr. Srinivas Akkaraju, MD, Ph.D. has voting and investment power over the securities held by Samsara Opportunity Fund and, accordingly, may be deemed to beneficially own the securities held by Samsara Opportunity Fund. Each of the Reporting Persons disclaims beneficial ownership in these securities except to the extent of its or his pecuniary interest therein.
F3: Represents a pro rata, in-kind distribution, without additional consideration, and not a purchase or sale of securities, by Samsara LP in respect of redeemed interests in Samsara LP. Of the shares distributed by Samsara LP, (i) 47,498 were distributed to redeeming limited partners, (ii) 14,937 shares were distributed to Samsara BioCapital GP, LLC ("Samsara LLC"), the general partner of Samsara LP, in respect of redeemed interests of non-managing members of Samsara LLC that were retained by Samsara LLC, and (iii) 4,471 shares were distributed to Samsara BioCapital Partners, L.P. ("Samsara BioCapital Partners"), in respect of the redeemed interest of a limited partner of Samsara LP that has been acquired by Samsara BioCapital Partners.
F4: The shares held by Samsara LP reflects the disposition of 244,300 shares, to Samsara Opportunity Fund as described in footnote (1), in which each of Samsara LLC and Dr. Akkaraju had no pecuniary interest.
F5: Securities are held by Samsara LP. Samsara LLC is the general partner of Samsara LP and may be deemed to beneficially own the shares held by Samsara LP. Dr. Akkaraju has voting and investment power over the shares held by Samsara LP and, accordingly, may be deemed to beneficially own the shares held by Samsara LP. Each of the Reporting Persons disclaims beneficial ownership in these shares except to the extent of its or his respective pecuniary interest therein.
F6: Represents receipt of shares in the distribution in kind described in footnote (3).
F7: Securities are held by Samsara LLC. Dr. Akkaraju has voting and investment power over the shares held by Samsara LLC and, accordingly, may be deemed to beneficially own the shares held by Samsara LLC. Each of the Reporting Persons disclaims beneficial ownership in these shares except to the extent of its or his respective pecuniary interest therein.
F8: Securities are held by Samsara BioCapital Partners. Dr. Akkaraju has voting and investment power over the shares held by Samsara BioCapital Partners and, accordingly, may be deemed to beneficially own the shares held by Samsara BioCapital Partners. Each of the Reporting Persons disclaims beneficial ownership in these shares except to the extent of its or his respective pecuniary interest therein.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 20, 2026 Filed May 22, 2026 23:47 UTC | Kalaris Therapeutics, Inc. KLRS · Entity 6805 | OtherCommon Stock | 4,471 | $0.00 | $0.00 |
DisclosureSEC source: 0001231919-26-000532 · form4-05222026_110527.xml · nonDerivative · entry 4 AKKARAJU SRINIVAS · CIK 0001253170 · Director · 10% owner Samsara BioCapital, L.P. · CIK 0001699737 · 10% owner Samsara BioCapital GP, LLC · CIK 0001888829 · 10% owner Samsara Opportunity Fund, L.P. · CIK 0002086193 · 10% owner Samsara Opportunity Fund GP, LLC · CIK 0002086456 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Samsara BioCapital Partners, L.P. Disclosed balance after: 19,408 F6 · kind: Represents receipt of shares in the distribution in kind described in footnote (3). F8 · ownership.nature: Securities are held by Samsara BioCapital Partners. Dr. Akkaraju has voting and investment power over the shares held by Samsara BioCapital Partners and, accordingly, may be deemed to beneficially own the shares held by Samsara BioCapital Partners. Each of the Reporting Persons disclaims beneficial ownership in these shares except to the extent of its or his respective pecuniary interest therein. Read SEC document |
| May 20, 2026 Filed May 22, 2026 23:47 UTC | Kalaris Therapeutics, Inc. KLRS · Entity 6805 | OtherCommon Stock | 14,937 | $0.00 | $0.00 |
DisclosureSEC source: 0001231919-26-000532 · form4-05222026_110527.xml · nonDerivative · entry 3 AKKARAJU SRINIVAS · CIK 0001253170 · Director · 10% owner Samsara BioCapital, L.P. · CIK 0001699737 · 10% owner Samsara BioCapital GP, LLC · CIK 0001888829 · 10% owner Samsara Opportunity Fund, L.P. · CIK 0002086193 · 10% owner Samsara Opportunity Fund GP, LLC · CIK 0002086456 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Samsara BioCapital GP, LLC Disclosed balance after: 14,937 F6 · kind: Represents receipt of shares in the distribution in kind described in footnote (3). F7 · ownership.nature: Securities are held by Samsara LLC. Dr. Akkaraju has voting and investment power over the shares held by Samsara LLC and, accordingly, may be deemed to beneficially own the shares held by Samsara LLC. Each of the Reporting Persons disclaims beneficial ownership in these shares except to the extent of its or his respective pecuniary interest therein. Read SEC document |
| May 20, 2026 Filed May 22, 2026 23:47 UTC | Kalaris Therapeutics, Inc. KLRS · Entity 6805 | OtherCommon Stock | 66,906 | $0.00 | $0.00 |
DisclosureSEC source: 0001231919-26-000532 · form4-05222026_110527.xml · nonDerivative · entry 2 AKKARAJU SRINIVAS · CIK 0001253170 · Director · 10% owner Samsara BioCapital, L.P. · CIK 0001699737 · 10% owner Samsara BioCapital GP, LLC · CIK 0001888829 · 10% owner Samsara Opportunity Fund, L.P. · CIK 0002086193 · 10% owner Samsara Opportunity Fund GP, LLC · CIK 0002086456 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Samsara BioCapital, L.P. Disclosed balance after: 10,657,028 F3 · kind: Represents a pro rata, in-kind distribution, without additional consideration, and not a purchase or sale of securities, by Samsara LP in respect of redeemed interests in Samsara LP. Of the shares distributed by Samsara LP, (i) 47,498 were distributed to redeeming limited partners, (ii) 14,937 shares were distributed to Samsara BioCapital GP, LLC ("Samsara LLC"), the general partner of Samsara LP, in respect of redeemed interests of non-managing members of Samsara LLC that were retained by Samsara LLC, and (iii) 4,471 shares were distributed to Samsara BioCapital Partners, L.P. ("Samsara BioCapital Partners"), in respect of the redeemed interest of a limited partner of Samsara LP that has been acquired by Samsara BioCapital Partners. F4 · balance_after: The shares held by Samsara LP reflects the disposition of 244,300 shares, to Samsara Opportunity Fund as described in footnote (1), in which each of Samsara LLC and Dr. Akkaraju had no pecuniary interest. F5 · ownership.nature: Securities are held by Samsara LP. Samsara LLC is the general partner of Samsara LP and may be deemed to beneficially own the shares held by Samsara LP. Dr. Akkaraju has voting and investment power over the shares held by Samsara LP and, accordingly, may be deemed to beneficially own the shares held by Samsara LP. Each of the Reporting Persons disclaims beneficial ownership in these shares except to the extent of its or his respective pecuniary interest therein. Read SEC document |
| May 20, 2026 Filed May 22, 2026 23:47 UTC | Kalaris Therapeutics, Inc. KLRS · Entity 6805 | PurchaseCommon Stock | 244,300 | $4.83 | $1,179,969.00 |
DisclosureSEC source: 0001231919-26-000532 · form4-05222026_110527.xml · nonDerivative · entry 1 AKKARAJU SRINIVAS · CIK 0001253170 · Director · 10% owner Samsara BioCapital, L.P. · CIK 0001699737 · 10% owner Samsara BioCapital GP, LLC · CIK 0001888829 · 10% owner Samsara Opportunity Fund, L.P. · CIK 0002086193 · 10% owner Samsara Opportunity Fund GP, LLC · CIK 0002086456 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Samsara Opportunity Fund, L.P. Disclosed balance after: 2,224,147 F1 · kind: Represents the purchase of shares from Samsara BioCapital, L.P. ("Samsara LP") in a privately negotiated transaction. F2 · ownership.nature: Securities are directly held by Samsara Opportunity Fund, L.P. ("Samsara Opportunity Fund"). Samsara Opportunity Fund GP, LLC ("Samsara Opportunity GP") is the general partner of Samsara Opportunity Fund and may be deemed to beneficially own the securities held by Samsara Opportunity Fund. Dr. Srinivas Akkaraju, MD, Ph.D. has voting and investment power over the securities held by Samsara Opportunity Fund and, accordingly, may be deemed to beneficially own the securities held by Samsara Opportunity Fund. Each of the Reporting Persons disclaims beneficial ownership in these securities except to the extent of its or his pecuniary interest therein. Read SEC document |
| December 22, 2025 Filed Dec 22, 2025 21:15 UTC | Kalaris Therapeutics, Inc. KLRS · Entity 6805 | GrantCommon Stock | 1,500,000 | $10.00 | $15,000,000.00 |
DisclosureSEC source: 0001231919-25-000652 · form4-12222025_091234.xml · nonDerivative · entry 1 AKKARAJU SRINIVAS · CIK 0001253170 · Director · 10% owner Samsara Opportunity Fund, L.P. · CIK 0002086193 · 10% owner Samsara Opportunity Fund GP, LLC · CIK 0002086456 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Samsara Opportunity Fund, L.P. Disclosed balance after: 1,500,000 F1 · ownership.nature: Securities are directly held by Samsara Opportunity Fund, L.P. ("Samsara Opportunity Fund"). Samsara Opportunity Fund GP, LLC ("Samsara Opportunity GP") is the general partner of Samsara Opportunity Fund and may be deemed to beneficially own the securities held by Samsara Opportunity Fund. Samsara Opportunity GP and Dr. Akkaraju have voting and investment power over the securities held by Samsara Opportunity Fund and, accordingly, may be deemed to beneficially own the securities held by Samsara Opportunity Fund. Each of the Reporting Persons disclaims beneficial ownership in these securities except to the extent of his or its respective pecuniary interest therein. Read SEC document |
| December 18, 2025 Filed Feb 18, 2026 01:15 UTC | Kalaris Therapeutics, Inc. KLRS · Entity 6805 | PurchaseCommon Stock | 479,847 | $10.42 | $5,000,005.74 |
DisclosureSEC source: 0001231919-26-000166 · form4-02182026_010226.xml · nonDerivative · entry 1 AKKARAJU SRINIVAS · CIK 0001253170 · Director · 10% owner Samsara BioCapital, L.P. · CIK 0001699737 · 10% owner Samsara BioCapital GP, LLC · CIK 0001888829 · 10% owner Samsara Opportunity Fund, L.P. · CIK 0002086193 · 10% owner Samsara Opportunity Fund GP, LLC · CIK 0002086456 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Samsara Opportunity Fund, L.P. Disclosed balance after: 1,979,847 F1 · kind: Represents the purchase of shares from Samsara BioCapital, L.P. ("Samsara LP") in a privately negotiated transaction. F2 · balance_after: Represents the number of shares held as of the date of this filing, including the shares purchased by Samsara Opportunity Fund, L.P. ("Samsara Opportunity Fund") on December 22, 2025, as reported in the reporting persons' Form 4 filed with the SEC on December 22, 2025 (the "Prior Report"). The Prior Report is deemed amended hereby. F3 · ownership.nature: Securities are directly held by Samsara Opportunity Fund. Samsara Opportunity Fund GP, LLC ("Samsara Opportunity GP") is the general partner of Samsara Opportunity Fund and may be deemed to beneficially own the securities held by Samsara Opportunity Fund. The Reporting Person has voting and investment power over the shares held by Samsara Opportunity Fund and, accordingly, may be deemed to beneficially own the shares held by Samsara Opportunity Fund. The Reporting Person disclaims beneficial ownership in these securities except to the extent of his pecuniary interest therein. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.